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Thymidine kinase2,3-Dihydroxy-quinoxaline, a small molecule that promotes ATPase catalytic activity of Herpes
Simplex Virus thymidine kinase (HSV-TK), was identiﬁed by virtual screening. This compound
competitively inhibited HSV-TK catalyzed phosphorylation of acyclovir with Ki = 250 lM (95% CI:
106–405 lM) and dose-dependently increased the rate of the ATP hydrolysis with KM = 112 lM
(95% CI: 28–195 lM). The kinetic scheme consistent with this experimental data is proposed.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.Thymidine kinase (TK, EC 2.7.1.21) catalyzes phosphorylation of
thymidine to TMP and plays a signiﬁcant role in the synthesis of
DNA and cell division. It operates in most eukaryotic cells as well
as in several viruses (HSV, HCMV, EBV) [1]. Viral TKs signiﬁcantly
differ in both speciﬁcity and selectivity from the human ones and
thus represent an attractive target for antiviral therapy [2].
Thymidine kinase of Herpes Simplex Virus type 1 (HSV-TK) was
successfully targeted by both selective inhibitors and substrate
prodrugs which are enzymatically converted to toxic compounds.
One of the most common antiviral drug, Acyclovir (ACV), is a
HSV-TK substrate which is converted to acyclo-guanosine mono-
phosphate (Acyclo-GMP). Further phosphorylation converts it to
Acyclo-GTP that lacks 30-OH and after incorporation into viral
DNA terminates its synthesis [3]. Compounds that possess their
antiviral activity through the direct inhibition of HSV-TK gained a
lot of attention [4–7] however none of them is clinically approved.
Here we report a novel mode of HSV-TK activity modulation by
a small molecule which results in a switch from kinase to ATPase
catalytic activity. Initially we aimed at identiﬁcation of novel frag-
ment HSV-TK inhibitors using virtual fragment screening approach
[8–10]. Model of the HSV-TK was constructed from PDB ID 1KI3[11] (TK UL23 from type 1 HSV strain 17), while highly homolo-
gous recombinant TK UL23 from acyclovir-sensitive strain L2 of
type 1 HSV was used in further experiments [12]. The activity of
the predicted hits was evaluated in the model reaction of acyclovir
phosphorylation by HSV-TK (Supporting information) which
closely resembles the properties of the thymidine phosphorylation.
Several selected compounds demonstrated IC50 in submillimolar
range which is typical for fragment drug candidates [13]. One of
the hits (2,3-dihydroxy-quinoxaline, DHQ, Fig. 1) not only inhib-
ited the phosphorylation of the ACV but also promoted the forma-
tion of the additional 32P-containing spot other than ATP and
ACV-P on the chromatogram (Fig. 2). Apparently it was not the
phospho-DHQ since non-enzymatic phosphorylation of DHQ with
POCl3 produced a very unstable compound that had different Rf.
Treatment of the thin layer chromatography (TLC) plate with
molybdate solution lead to the speciﬁc blue coloring of the
unknown spot, clearly indicating that it was the orthophosphate.
Incubations of the enzyme-free mixtures containing only DHQ
(0–400 lM) and [c-32P] ATP demonstrated no phosphate forma-
tion (Fig. 5) thus indicating the involvement of the HSV-TK enzyme
in the DHQ promotion of ATP hydrolysis. To our knowledge this is
the ﬁrst case of the ATPase activity of the HSV-TK promoted by a
small molecule and we performed additional kinetic experiments
to explore the mechanism of mixed inhibitory and activatory mode
of DHQ action.
To elucidate the type of inhibition, kinetics of ACV phosphoryla-
tion was examined at varying concentrations of substrate (ACV)
Fig. 1. Predicted binding pose of DHQ with HSV-TK.
Fig. 2. Autoradiograph of TLC of ACV + DHQ + HSV-TK + ATP incubation mixtures on
PEI-cellulose in 1 M KH2PO4. Incubation time: 1, 2, 6, 7 – 1 h, 3, 4, 5 – 10, 20 and
30 min, respectively. Spots correspond to ATP, ACV-P and Pi (starting from the
bottom). For detailed reaction conditions see Supporting information.
Fig. 3. Eadie–Hofstee linearization of ACV phosphorylation inhibition by DHQ.
Fig. 4. Autoradiograph of TLC of DHQ + HSV-TK + ATP incubation mixtures on PEI-
cellulose in 1 M KH2PO4. Incubation time: 1 – 60 min, 2, 3, 4 – 10, 20, 40 min,
respectively. Spots correspond to ATP, and Pi (starting from the bottom). For
detailed reaction conditions see Supporting information.
Fig. 5. DHQ-promoted HSV-TK catalyzed hydrolysis of ATP.
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Hofstee coordinates (Fig. 3) produced a series of parallel lines for
different DHQ concentrations that clearly indicated the competi-
tive mode of inhibition. Subsequent non-linear ﬁt gave Ki = 250 lM
(95% CI: 106–405 lM). Hydrolysis of ATP also occurred in the
studied reaction mixtures, and at high DHQ levels its rate was
comparable with the rate of ACV phosphorylation (113 and
133 nM/min for 400 lM DHQ/100 lM ACV mixture, respectively)
demonstrating the shift of the reaction direction from kinase-type
to ATPase-type.
Sole ATPase reaction was observed in incubations of ATP with
HSV-TK and increasing concentrations of DHQ (Fig. 4). The
resulting data ([ATP] = 330 lM) were ideally ﬁtted by a Michaelis–
Menten equation (Fig. 5) with KM = 112 lM (95% CI: 28–195 lM)
thus again indicating the involvement of the enzyme.
We have proposed an enzymatic kinetic scheme that qualita-
tively describes the obtained results. The catalytic mechanism ofthe HSV-TK is unknown, however for the similar (in the functional
aspect) human thymidylate kinase an unordered bi-bi mechanism
was proposed [14]. In the present study ATP acts as a phosphate
donor, ACV and DHQ – as substrates, and the generalized kinetic
scheme can be represented as in Scheme 1 (under the quasi-equi-
librium assumption for substrate binding stages).
For the DHQ-promoted ATP hydrolysis in the absence of the
ACV the initial rate of phosphate formation can be expressed as:
Scheme 1. Kinetic scheme of the ACV phosphorylation and DHQ-catalyzed
hydrolysis of ATP by HSV-TK.
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dt
¼ kDHQ ½E0½DHQ ½ATP
K 0DHQKATP þ K 00ATP½DHQ  þ K 0DHQ ½ATP þ ½DHQ ½ATP
Since the concentration of ATP was constant for all experiments, the
equation can be reformulated in terms of apparent kinetic
constants:
d½Pi
dt
¼ kDOC½E0½DOC½ATPðK 0DOCKATP þ K 0DOC½ATPÞ þ ½DOCðK 00ATP þ ½ATPÞ
¼ V
DOC
m;app½DOC
KDOCm;app þ ½DOC
;
where Vappm and K
app
m are independent on the DHQ level and the
apparent reaction kinetics obeys the Michaelis–Menten rule.
KDHQm;app is expressed as:
KDHQm;app ¼ K 0DHQ
KATP þ ½ATP
K 00ATP þ ½ATP
In the complete system (ATP + DHQ + ACV) the rate of ACV
phosphorylation is expressed as: d½ACV—Pdt ¼
KACV ½E0 ½ACV½ATP
K 0ACVKATPþK 0ACV ½ATPþK 0ATP ½ACVþ½ACV½ATPþ½DHQ 
K0
ACV
K00
ATP
K0
DHQ
þ½DHQ ½ATP
K0
ACV
K0
DHQ
which again
can be transformed to Michaelis–Menten form:
’
d½ACV—P
dt
¼ V
0ACV
m;app½ACV
K 0ACVm;app þ ½ACV
;
where V 0ACVm;app depends only on the [ATP], while K
0ACV
m;app is dependent
on both [ATP] and [DHQ]:
K 0ACVm;app ¼
K 0ACVKATP þ K 0ACV½ATP þ ½DHQ  K
0
ACVK
00
ATP
K 0DHQ
þ ½DHQ ½ATP K 0ACVK 0DHQ
K 0ATP þ ½ATP
;
that can be rewritten as:
K 0ACVm;app ¼ K 0ACV
KATP þ ½ATP
K 0ATP þ ½ATP
 
þ K 0ACV
KATP þ ½ATP
K 0ATP þ ½ATP
 
 ½DHQ  K
00
ATP þ ½ATP
K 0DHQ ðKATP þ ½ATPÞ
¼ KACVm;app 1þ
½DOC
KDHQI;app
 !
This equation corresponds to the competitive inhibition of the ACV
phosphorylation by DHQ, and the expression for KDOCI;app is the same as
for KDOCm;app.
According to the proposed kinetic model of ATP hydrolysis
promotion, Ki for the inhibition of the ACV hydrolysis and KM for
DHQ for the ATPase reaction should be the same. The obtained
values (KM = 250 lM, 95% CI: 106–405 lM and Ki = 112 lM, 95%
CI: 28–195 lM) are quite close and can be considered equal within
the experimental error thus demonstrating that the proposedkinetic scheme doesn’t conﬂict with the experimental data. How-
ever additional mechanistic studies are required to unambiguously
identify the detailed reaction pathway and the fate of the DHQ
which can either remain unchanged during the reaction or it can
be converted to non-radioactive product as well.
In summary, we have discovered a novel mode of enzyme activ-
ity modulation by a small molecule and proposed a kinetic scheme
that describes the obtained experimental results. Detailed studies
of such ligand–protein interactions potentially allow the develop-
ment of the drugs with the novel mechanism of action and are
surely of high scientiﬁc impact.
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